ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Taraxerol Alleviates Cerebral Ischemia-Reperfusion Induced Inflammation and Ferroptosis via Regulating AKT/NF-κB Pathway.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Taraxerol (Tar) is a natural triterpenoid which exhibited anti-inflammatory and neuroprotective properties. Whereas, the roles of Tar in cerebral ischemia-reperfusion injury (CIRI) remain incompletely understood. The research investigated the protective effects and regulatory mechanism of Tar in CIRI. The middle cerebral artery occlusion (MCAO) model was established in vivo. Effects of Tar on brain injury and MCAO rats motor function were detected by HE staining and TUNEL assay. PC12 cells were subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) and irritated with 20, 40, 80, and 160 μM Tar; the intracellular Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.